<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03446534</url>
  </required_header>
  <id_info>
    <org_study_id>2017/1863</org_study_id>
    <nct_id>NCT03446534</nct_id>
  </id_info>
  <brief_title>The Norwegian Antibiotics for Pneumonia in Children Study</brief_title>
  <acronym>NAPiC</acronym>
  <official_title>The Norwegian Antibiotics for Pneumonia in Children Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ostfold Hospital Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Helse Stavanger HF</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Haukeland University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Alesund Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Olavs Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nordlandssykehuset HF</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital of North Norway</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Akershus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Norwegian Institute of Public Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>KLINBEFORSK</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the effect of amoxicillin in the treatment of lower airway infections in
      preschool children. Half of the patients will receive amoxicillin, while the other half will
      receive placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The overall objective of the study is to determine if antibiotic therapy is beneficial in
      children with pneumonia who do not have a highly suspicious bacterial infection, such as in
      lobar pneumonia.

      Secondary objective is to determine whether antibiotic use influence the microbial flora,
      including antibiotic resistance, in the airways in the short or medium long term.

      The study is a phase IV double-blind, placebo-controlled, multicenter, nationwide, randomized
      superiority trial of amoxicillin versus placebo in children aged 1-5 years of age with a
      lower respiratory infection.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 7, 2018</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The study is a phase IV double-blind, placebo-controlled, multicenter, nationwide, randomized superiority trial of amoxicillin versus placebo in children aged 1-5 years of age with a lower respiratory infection.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Therapy Failure</measure>
    <time_frame>Within 7 days after inclusion</time_frame>
    <description>Therapy failure as defined by attending physician, leading to end of intervention and administration of open-label antibiotics</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Thereapy failure leading to intravenous antibiotic therapy</measure>
    <time_frame>Within 7 days after inclusion</time_frame>
    <description>Therapy failure as defined by attending physician, leading to intravenous antibiotic therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of fever</measure>
    <time_frame>Up to 21 days after inclusion</time_frame>
    <description>Duration of fever</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of symptoms of pneumonia</measure>
    <time_frame>Up to 21 days after inclusion</time_frame>
    <description>Duration of cough or respiratory distress (tachypnoe, retractions, grunting respiration or nasal flaring.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">884</enrollment>
  <condition>Pneumonia Childhood</condition>
  <condition>Lower Respiratory Tract Infection</condition>
  <arm_group>
    <arm_group_label>Amoxicillin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Amoxicillin 100mg/ml mixture (Imacillin), 0.25ml/kg every 8 hours for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo mixture 0.25ml/kg every 8 hours for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin</intervention_name>
    <description>Imacillin mixture</description>
    <arm_group_label>Amoxicillin</arm_group_label>
    <other_name>Imacillin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Placebo manufactured to mimic amoxicillin mixture (Imacillin)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 12-59 months

          2. Fever:

             a. Temperature ≥ 38.0 at inclusion or reported within the last 24 hours

          3. Tachypnoe, age specific 12-17mnd ≥ 46 breaths per minute 18-23mnd ≥ 40 breaths per
             minute 24-35mnd ≥ 34 breaths per minute 36-47mnd ≥ 29 breaths per minute 48-59mnd ≥ 27
             breaths per minute

          4. ≥ 1 sign of lower airway inflammation

               1. Cough (at inclusion or reported within the last 6 hours)

               2. Chest retractions (jugular, intercoastally or subcoastally)

               3. Grunting respiration

               4. Nasal flaring

               5. Crepitations by pulmonary auscultation

               6. Hypoxia (SpO2 ≤ 90%)

          5. Weight between 6.0 and 28.0 kg. • Signed informed consent and expected cooperation of
             the patients for the treatment and follow up must be obtained and documented according
             to ICH GCP, and national/local regulations

        Exclusion Criteria:

          1. Clinical suspicion of bacterial pneumonia based upon a temperature ≥39.0°C and at
             least one of the following:

               1. Bronchial breathing sounds

               2. Unilaterally decreased breath sounds or unilateral percussion dullness

               3. Pulmonary lobar consolidation and/or radiological high suspicion of empyema on
                  chest x-ray if this is obtained prior to inclusion in the trial.

          2. Evidence of any bacterial infection requiring systemic antibiotics, including, but not
             exclusively:

               1. Clinical septicaemia

               2. Urinary tract infection

               3. Meningitis

          3. Systemic antibiotics received within the last 7 days

          4. Pulmonary lobar consolidation and/or radiological high suspicion of empyema on chest
             x-ray if this is obtained prior to inclusion in the trial.

          5. History of any serious underlying disease that can increase the risk of bacterial
             pulmonary infections, including but not limited to:

               1. Haematological or oncological

               2. Immunodeficiency

               3. Congenital heart disease

               4. Neuromuscular impairment

               5. Development disorder, including Downs syndrome

               6. Bronchopulmonary dysplasia, cystic fibrosis, primary ciliary dyskinesia, poorly
                  controlled asthma or other severe chronic lung diseases

          6. Signs of lower obstructive airways with both of the following present by auscultation:

               1. prolonged expiration and

               2. generalised expiratory wheeze

          7. Stridor by auscultation.

          8. History of known or suspected adverse reactions to amoxicillin, or any other
             betalactam

          9. Participating in another trial that might affect the current study

         10. Any reason why, in the opinion of the investigator, the patient should not participate
             (e.g. not able to comply with study procedures)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>59 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Håvard O Skjerven</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oslo University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Håvard O Skjerven, PhD</last_name>
    <phone>+47 41020249</phone>
    <email>h.o.skjerven@medisin.uio.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Per Kristian Knudsen, MD</last_name>
    <phone>+4791631421</phone>
    <email>perkristiank@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Haukeland University Hospital</name>
      <address>
        <city>Bergen</city>
        <zip>5021</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Håvard Trønnes, PhD</last_name>
      <phone>95777862</phone>
      <email>havard.tronnes@ihelse.net</email>
    </contact>
    <investigator>
      <last_name>Håvard Trønnes, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nordlandssykehuset Bodø</name>
      <address>
        <city>Bodø</city>
        <zip>8005</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bjørg Evjenth</last_name>
      <phone>99258992</phone>
      <email>bjorg.evjenth@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Bjørg Evjenth, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Østfold Hospital Trust</name>
      <address>
        <city>Grålum</city>
        <zip>1714</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jon Olav Hunderi, MD</last_name>
      <phone>91880816</phone>
      <email>jon.olav.gjengsto.hunderi@so-hf.no</email>
    </contact>
    <investigator>
      <last_name>Jon Olav Hunderi, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Akershus University Hospital</name>
      <address>
        <city>Lørenskog</city>
        <zip>1478</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christopher Inchley</last_name>
      <phone>90069276</phone>
      <email>christopher.inchley@medisin.uio.no</email>
    </contact>
    <investigator>
      <last_name>Christopher Inchley, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oslo University of Oslo</name>
      <address>
        <city>Oslo</city>
        <zip>0424</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Håvard O Skjerven, PhD</last_name>
      <phone>41020249</phone>
      <email>h.o.skjerven@medisin.uio.no</email>
    </contact>
    <contact_backup>
      <phone_ext>Skjerven</phone_ext>
      <email>h.o.skjerven@medisin.uio.no</email>
    </contact_backup>
    <investigator>
      <last_name>Håvard O Skjerven, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Per Kristian Knudsen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stavanger University Hospital</name>
      <address>
        <city>Stavanger</city>
        <zip>4011</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Knut Øymar, PhD</last_name>
      <phone>41633426</phone>
      <email>knut.oymar@sus.no</email>
    </contact>
    <investigator>
      <last_name>Knut Øymar, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Northern Norway</name>
      <address>
        <city>Tromsø</city>
        <zip>9038</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claus Klingenberg</last_name>
      <phone>91563167</phone>
      <email>claus.klingenberg@unn.no</email>
    </contact>
    <investigator>
      <last_name>Claus Klingenberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Olav University Hospital</name>
      <address>
        <city>Trondheim</city>
        <zip>7030</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Henrik Döllner, PhD</last_name>
      <phone>47667169</phone>
      <email>henrik.dollner@ntnu.no</email>
    </contact>
    <investigator>
      <last_name>Henrik Döllner, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ålesund Hospital Trust</name>
      <address>
        <city>Ålesund</city>
        <zip>6017</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Torbjørn Nag</last_name>
      <phone>41638349</phone>
      <email>torbjorn.nag@helse-mr.no</email>
    </contact>
    <investigator>
      <last_name>Torbjørn Nag, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 17, 2018</study_first_submitted>
  <study_first_submitted_qc>February 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2018</study_first_posted>
  <last_update_submitted>April 10, 2018</last_update_submitted>
  <last_update_submitted_qc>April 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Håvard Ove Skjerven</investigator_full_name>
    <investigator_title>Consultant</investigator_title>
  </responsible_party>
  <keyword>pneumonia</keyword>
  <keyword>pre-school children</keyword>
  <keyword>antibiotics</keyword>
  <keyword>amoxicillin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

